|
業務類別
|
Biotechnology |
|
業務概覽
|
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. |
| 公司地址
| 10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA, USA, 90024 |
| 電話號碼
| +1 424 248-6500 |
| 傳真號碼
| +1 424 248-6501 |
| 公司網頁
| https://www.pumabiotechnology.com |
| 員工數量
| 172 |
| Mr. Alan H. Auerbach |
Chairman of the Board, President, Chief Executive Officer and Secretary |
美元 904.21K |
26/02/2026 |
| Mr. Maximo F. Nougues |
Chief Financial Officer and Principal Accounting Officer |
美元 538.72K |
26/02/2026 |
| Mr. Douglas M. Hunt |
Chief Regulatory Affairs, Medical Affairs and Pharmacovigilance Officer |
美元 461.89K |
28/04/2025 |
|
|
| Mr. Alan H. Auerbach |
Chairman of the Board, President, Chief Executive Officer and Secretary |
26/02/2026 |
| Mr. Michael Patrick Miller |
Independent Director |
26/02/2026 |
| Mr. Jay M. Moyes |
Lead Independent Director |
26/02/2026 |
| Dr. Alessandra Cesano, M.D. |
Independent Director |
26/02/2026 |
| Mr. Brian M. Stuglik, R.Ph. |
Independent Director |
26/02/2026 |
| Ms. Allison Dorval |
Independent Director |
26/02/2026 |
| Dr. Adrian M. Senderowicz, M.D. |
Independent Director |
26/02/2026 |
| Dr. Troy E. Wilson, PhD, J.D. |
Independent Director |
26/02/2026 |
|
|
|
|
